* Protara Therapeutics Inc TARA.OQ TARA.O is expected
to show
no change in quarterly revenue when it reports results on
November 1 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Protara Therapeutics Inc
is
for a loss of 52 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Protara
Therapeutics Inc is 23.00, above its last closing price
of $2.34.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.96 -0.80 -0.45 Beat 43.8
Jan. 1 2024 -0.86 -0.97 -5.4
Dec. 31 2023 -0.92 -0.90 Beat 1.9
Jan. 1 0001 -1.04 -0.98 -0.87 Beat 11.2
Jun. -0.88 -0.87 -1.00 Missed -14.3
30 2023
Mar. 31 2023 -0.91 -0.88 -0.80 Beat 8.8
Dec. 31 2022 -0.75 -1.55 Missed -106.7
Jan. 1 0001 -0.77 -0.76 -0.68 Beat 10.1
This summary was machine generated October 30 at 13:23 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)